Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Hemostasis of Active Gastrointestinal (GI) Luminal Tract Bleeding (HALT)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2016 by Cook
Information provided by (Responsible Party):
Cook Identifier:
First received: February 17, 2011
Last updated: August 16, 2016
Last verified: August 2016

February 17, 2011
August 16, 2016
December 2011
March 2019   (final data collection date for primary outcome measure)
Proportion of patients with further bleed [ Time Frame: 72 Hours ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01306864 on Archive Site
Proportion of patients with initial hemostasis [ Time Frame: At the conclusion of the index procedure ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Hemostasis of Active Gastrointestinal (GI) Luminal Tract Bleeding
Clinical Evaluation of Hemospray: Hemostasis of Active GI Luminal Tract Bleeding
The objective of this study is to show that Hemospray is effective in achieving initial hemostasis and documenting rate of further bleed when compared to standard of care.
Not Provided
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Bleeding Peptic Ulcers
Device: Hemospray Kit
Hemostasis of Arterial GI Bleeding
Other Name: Endoscopic Hemostasis
Experimental: Hemospray Treatment
Hemospray Kit
Intervention: Device: Hemospray Kit
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
March 2019
March 2019   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Bleeding peptic ulcer

Exclusion Criteria:

  • Patient is: < 18 years of age
  • Patient is unable to consent
  • Patient is contraindicated to undergo endoscopy
  • Patient has: coagulopathy, altered post surgical anatomy of the stomach, previously placed intrahepatic portosystemic shunt
  • Patient is pregnant or lactating
  • Patinet has an INR > 2.5
18 Years and older   (Adult, Senior)
Contact: Julie Whitaker 765-463-7537
Contact: Levi Kosta-Mikel 765-463-7537
Canada,   Hong Kong,   Netherlands,   United Kingdom
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP